Morbidity and Mortality Weekly Report: Recommendations and Reports, November 17, 2023 / Vol. 72 / No. RR-6

Details

• Alternative Title:
  CDC Guidelines for the Prevention and Treatment of Anthrax, 2023
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Bower, William A. ; Yu, Yon ; Person, Marissa K. ; Parker, Corinne M. ; Kennedy, Jordan L. ; Sue, David ; Hesse, Elisabeth M. ; Cook, Rachel ; Bradley, John ; Bulitta, Jürgen B. ; Karchmer, Adolf W. ; Ward, Robert M. ; Cato, Shana Godfred ; Stephens, Kevin Chatham ; Hendricks, Katherine A.
• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology. ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Preparedness and Emerging Infections. ; University of California San Diego School of Medicine. ; University of Florida College of Pharmacy. ; Beth Israel Deaconess Medical Center. ; University of Utah School of Medicine. ; National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention). Division of Birth Defects and Infant Disorders. ; National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention). Division of Human Development and Disability.
• Description:
  This report updates previous cdc guidelines and recommendations on preferred prevention and treatment regimens regarding naturally occurring anthrax. Also provided are a wide range of alternative regimens to first-line antimicrobial drugs for use if patients have contraindications or intolerances or after a wide-area aerosol release of: Bacillus anthracis spores if resources become limited or a multidrug-resistant B. anthracis strain is used (Hendricks KA, Wright ME, Shadomy SV, et al.; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014;20:e130687; Meaney-Delman D, Rasmussen SA, Beigi RH, et al. Prophylaxis and treatment of anthrax in pregnant women. Obstet Gynecol 2013;122:885-900; Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014;133:e1411-36). Specifically, this report updates antimicrobial drug and antitoxin use for both postexposure prophylaxis (PEP) and treatment from these previous guidelines best practices and is based on systematic reviews of the literature regarding 1) in vitro antimicrobial drug activity against B. anthracis; 2) in vivo antimicrobial drug efficacy for PEP and treatment; 3) in vivo and human antitoxin efficacy for PEP, treatment, or both; and 4) human survival after antimicrobial drug PEP and treatment of localized anthrax, systemic anthrax, and anthrax meningitis.
  
  Changes from previous cdc guidelines and recommendations include an expanded list of alternative antimicrobial drugs to use when first-line antimicrobial drugs are contraindicated or not tolerated or after a bioterrorism event when first-line antimicrobial drugs are depleted or ineffective against a genetically engineered resistant: B. anthracis strain. In addition, these updated guidelines include new recommendations regarding special considerations for the diagnosis and treatment of anthrax meningitis, including comorbid, social, and clinical predictors of anthrax meningitis. The previously published CDC guidelines and recommendations described potentially beneficial critical care measures and clinical assessment tools and procedures for persons with anthrax, which have not changed and are not addressed in this update. In addition, no changes were made to the Advisory Committee on Immunization Practices recommendations for use of anthrax vaccine (Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep 2019;68[No. RR-4]:1-14). The updated guidelines in this report can be used by health care providers to prevent and treat anthrax and guide emergency preparedness officials and planners as they develop and update plans for a wide-area aerosol release of B. anthracis.
  
  
• Subjects:
  Adult Aerosols Anthrax / Prevention & Control Anthrax Vaccines Anti-Infective Agents Antitoxins Bacillus Anthracis Child Female Humans Meningitis Pregnancy United States

  More +
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2023; v. 72, no. 6
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  1057-5987 (print) ; 1545-8601 (digital)
• Document Type:
  Journal Issue
• Place as Subject:
  United States
• Pages in Document:
  50 pdf pages
• Volume:
  72
• Issue:
  6
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:1cbfc342d63ecea4dbd97a6fe28edb43b22f45a5b3b081159464f0f12499766f9d67761d7aa24d260ed3e5a13f930412c951ad783b7d83581a644cdca957f283
• Download URL:
  https://stacks.cdc.gov/view/cdc/136449/cdc_136449_DS1.pdf
• File Type:
  [PDF - 768.57 KB ]